Derived neutrophil-to-lymphocyte ratio has the potential to predict safety and outcomes of durvalumab after chemoradiation in non-small cell lung cancer

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Scientific Reports

Topics

Medicine

Cancer Oncology

Internal Medicine

Surgery

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1038/s41598-024-70214-y

License

CC-BY